A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) (NCT05002127)

🧪 Interventions in This Study

• Evorpacept (ALX148) (DRUG)
• Trastuzumab (DRUG)
• Ramucirumab (DRUG)
• Paclitaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (83 Sites)

Showing the first 25 of 83 sites.

• The Oncology Institute of Hope & Innovation — Anaheim, California
• University of California Los Angeles — Los Angeles, California
• Vanderbilt University Medical Center — Nashville, Tennessee
• NEXT Virginia — Fairfax, Virginia
• Fred Hutchinson Cancer Center — Seattle, Washington
• Icon Cancer Centre Southport — Southport, Queensland
• Monash Medical Centre — Clayton, Victoria
• Universitair Ziekenhuis Antwerpen — Antwerp,
• Universitair Ziekenhuis Leuven - Campus Gasthuisberg — Leuven,
• Centre Hospitalier Universitaire de Liège — Liège,
• Fakultní Nemocnice Hradec Králové — Hradec Králové,
• Fakultní Nemocnice Olomouc — Olomouc,
• Vseobecna Fakultni Nemocnice v Praze — Prague,
• Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz — Besançon,
• Centre Hospitalier Universitaire de Bordeaux — Bordeaux,
• Hôpital Morvan — Brest,
• Centre Léon Bérard — Lyon,
• Hôpital Privé Jean Mermoz — Lyon,
• Institut Paoli-Calmettes — Marseille,
• Hôpital Saint-Antoine — Paris,
• Hôpital Trousseau — Paris,
• Hôpital Rangueil — Toulouse,
• Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi — Catania,
• Azienda Ospedaliero - Universitaria Careggi — Florence,
• Fondazione IRCCS - Istituto Nazionale dei Tumori — Milan,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Gastric Cancer

• A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Scottsdale, Arizona
• Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer — Los Angeles, California
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) — Baltimore, Maryland
• Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer — Baltimore, Maryland
• Study for AZD4360 in Participants With Advanced Solid Tumours — Santa Monica, California
• Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma — Tampa, Florida

Explore by condition: All Gastric Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.